Literature DB >> 2246613

Lysosomal acid lipase deficiency in rats: lipid analyses and lipase activities in liver and spleen.

M Kuriyama1, H Yoshida, M Suzuki, J Fujiyama, A Igata.   

Abstract

We report the biological characterization of an animal model of a genetic lipid storage disease analogous to human Wolman's disease. Affected rats accumulated cholesteryl esters (13.3-fold), free cholesterol (2.8-fold), and triglycerides (5.4-fold) in the liver, as well as cholesteryl esters (2.5-fold) and free cholesterol (1.33-fold) in the spleen. Triglycerides did not accumulate, and the levels actually decreased in the spleen. Analysis of the fatty acid composition of the cholesteryl esters and triglycerides showed high percentages of linoleic acid (18:2) and arachidonic acid (20:4) in both organs, especially in the liver. No accumulation of phospholipids, neutral glycosphingolipids, or gangliosides was found in the affected rats. Acid lipase activity for [14C]triolein, [14C]cholesteryl oleate, and 4-methyl-umbelliferyl oleate was deficient in both the liver and spleen of affected rats. Lipase activity at neutral pH was normal in both liver and spleen. Heterozygous rats showed intermediate utilization of these substrates in both organs at levels between those for affected rats and those for normal controls, although they did not accumulate any lipids. These data suggest that these rats represent an animal counterpart of Wolman's disease in humans.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2246613

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  11 in total

1.  Hepatic entrapment of esterified cholesterol drives continual expansion of whole body sterol pool in lysosomal acid lipase-deficient mice.

Authors:  Amal Aqul; Adam M Lopez; Kenneth S Posey; Anna M Taylor; Joyce J Repa; Dennis K Burns; Stephen D Turley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-08-21       Impact factor: 4.052

2.  Systemic administration of 2-hydroxypropyl-β-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function.

Authors:  Adam M Lopez; Sandi J Terpack; Kenneth S Posey; Benny Liu; Charina M Ramirez; Stephen D Turley
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-10       Impact factor: 2.557

3.  Deletion of sterol O-acyltransferase 2 (SOAT2) function in mice deficient in lysosomal acid lipase (LAL) dramatically reduces esterified cholesterol sequestration in the small intestine and liver.

Authors:  Adam M Lopez; Kenneth S Posey; Stephen D Turley
Journal:  Biochem Biophys Res Commun       Date:  2014-10-18       Impact factor: 3.575

4.  Lysosomal acid lipase promotes cholesterol ester metabolism and drives clear cell renal cell carcinoma progression.

Authors:  Jun Wang; Mingyue Tan; Jifu Ge; Ping Zhang; Jie Zhong; Le Tao; Qiong Wang; Xuemei Tong; Jianxin Qiu
Journal:  Cell Prolif       Date:  2018-03-23       Impact factor: 6.831

5.  Molecular markers of brain cholesterol homeostasis are unchanged despite a smaller brain mass in a mouse model of cholesteryl ester storage disease.

Authors:  Amal A Aqul; Charina M Ramirez; Adam M Lopez; Dennis K Burns; Joyce J Repa; Stephen D Turley
Journal:  Lipids       Date:  2021-10-07       Impact factor: 1.880

6.  The lipofuscin fluorophore A2E perturbs cholesterol metabolism in retinal pigment epithelial cells.

Authors:  Aparna Lakkaraju; Silvia C Finnemann; Enrique Rodriguez-Boulan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

7.  PRD125, a potent and selective inhibitor of sterol O-acyltransferase 2 markedly reduces hepatic cholesteryl ester accumulation and improves liver function in lysosomal acid lipase-deficient mice.

Authors:  Adam M Lopez; Jen-Chieh Chuang; Kenneth S Posey; Taichi Ohshiro; Hiroshi Tomoda; Lawrence L Rudel; Stephen D Turley
Journal:  J Pharmacol Exp Ther       Date:  2015-08-17       Impact factor: 4.030

8.  Impact of loss of SOAT2 function on disease progression in the lysosomal acid lipase-deficient mouse.

Authors:  Adam M Lopez; Jen-Chieh Chuang; Stephen D Turley
Journal:  Steroids       Date:  2017-12-13       Impact factor: 2.668

9.  Ezetimibe markedly attenuates hepatic cholesterol accumulation and improves liver function in the lysosomal acid lipase-deficient mouse, a model for cholesteryl ester storage disease.

Authors:  Jen-Chieh Chuang; Adam M Lopez; Kenneth S Posey; Stephen D Turley
Journal:  Biochem Biophys Res Commun       Date:  2013-12-25       Impact factor: 3.575

Review 10.  Targeting Wolman Disease and Cholesteryl Ester Storage Disease: Disease Pathogenesis and Therapeutic Development.

Authors:  Francis Aguisanda; Natasha Thorne; Wei Zheng
Journal:  Curr Chem Genom Transl Med       Date:  2017-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.